Oncology Learning Network
Verified
Online/Digital
Oncology Learning Network® is an online resource for the latest developments in oncology practice, providing a customized experience for readers to stay informed about the topics that matter most to them. Through clinical insights, peer-reviewed journal articles, interactive features, research news updates, accredited continuing educational programs, and professional live meetings and events, Oncology Learning Network serves as a collaborative learning and networking environment for a multidisciplinary community of oncology medical professionals.
As the digital home to the respected and well-known online and live continuing education programs in oncology provided by Imedex and NACCME, Oncology Learning Network allows busy oncology providers to meet all of their educational and informational needs in one place. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesFDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
News Clinical Summary: Design/Population: EXCALIBER-RRMM was a multicenter, open-label trial evaluating iberdomide plus daratumumab and hyaluronidase and dexamethasone in adults with relapsed or refractory multiple myeloma who had received 1 or 2 prior lines of therapy. Key Outcomes: Iberdomide plus daratumumab and dexamethasone achieved an MRD-negative complete response rate of 41% compared with 21% with daratumumab plus bortezomib and dexamethasone (P < .0001).
Perioperative Enfortumab Vedotin Plus Pembrolizumab Outperforms Cisplatin Plus Gemcitabine in Muscle-Invasive Bladder Cancer
Clinical Summary: Design/Population: The phase 3 KEYNOTE-B15/EV-304 trial evaluated perioperative enfortumab vedotin plus pembrolizumab compared with standard neoadjuvant cisplatin plus gemcitabine in patients with cisplatin-eligible muscle-invasive bladder cancer.
BEGONIA Shows No Added Benefit With Capivasertib or Oleclumab Added to Durvalumab Plus Paclitaxel in Advanced Triple-Negative Breast Cancer
Clinical Summary: Design/Population: The phase 1b/2 BEGONIA study evaluated first-line durvalumab-based combinations in patients with previously untreated, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Key Outcomes: Confirmed objective response rates were 56.5% with durvalumab plus paclitaxel, 54.8% with the addition of capivasertib, and 51.5% with the addition of oleclumab.
Subcutaneous Pertuzumab Plus Trastuzumab Shows Comparable 4-Year Outcomes to Intravenous Therapy in HER2-Positive Breast Cancer
Clinical Summary: Design/Population: The phase 3 FeDeriCa compared a fixed-dose subcutaneous combination of pertuzumab plus trastuzumab with intravenous pertuzumab plus trastuzumab in patients with HER2-positive operable, locally advanced, or inflammatory stage II to IIIC breast cancer. Key Outcomes: At approximately 4 years of follow-up, long-term invasive disease-free survival, event-free survival, distant recurrence-free interval, and overall survival were comparable between treatment groups.
Long-Term Follow-Up Demonstrates Improved Outcomes With Two-Site Peptide Vaccination in Melanoma
Clinical Summary: Design/Population: This long-term follow-up of a multicenter melanoma vaccine trial evaluated peptide vaccination with Montanide ISA-51 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF). The study also compared administration of the vaccine at one injection site versus two injection sites. Key Outcomes: Adding GM-CSF did not improve immune responses or long-term clinical outcomes.
Sonrotoclax Monotherapy Demonstrates Meaningful Activity in Heavily Pretreated Mantle Cell Lymphoma
Clinical Summary: Design/Population: The global, phase 1/2 BGB-11417-201 trial evaluated sonrotoclax monotherapy in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based therapy and a covalent or noncovalent BTK inhibitor. Key Outcomes: At the recommended phase 2 dose of 320 mg once daily, sonrotoclax achieved a 52.4% overall response rate versus 30% historically (P < .0001), with a 15.5% complete response rate.
Foundation AI Model Surpasses Early-Career Dermatologists but Falls Short of Experts in Skin Cancer Diagnosis
Clinical Summary: Design/Population: Multicenter diagnostic study comparing 652 physician readers with 3 artificial intelligence (AI) models using 1,117 clinical and dermoscopic skin lesion cases representing real-world practice. Key Outcomes: Expert dermatologists achieved the highest diagnostic accuracy (74.2%), outperforming all AI models. A modern unimodal foundation model (72.2%) exceeded physicians with fewer than 3 years of experience, while a first-generation CNN performed worst (56.7%).
Two Injection Sites Outperformed Single-Site Delivery for Melanoma Peptide Vaccine
Clinical Summary: Design/Population: This multicenter, randomized phase 2 trial evaluated a vaccine composed of 12 class I major histocompatibility complex–restricted melanoma peptides, administered with or without granulocyte–macrophage colony-stimulating factor (GM-CSF) and at either 1 or 2 injection sites, in patients with resected high-risk melanoma. Key Outcomes: Vaccination at 2 sites was associated with significantly improved recurrence-free survival compared with vaccination at 1 site.
Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
Clinical Summary: Design/Population: AdvanTIG-302 was a phase 3 trial evaluating first-line ociperlimab plus tislelizumab in patients with previously untreated stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%. Key Outcomes: Ociperlimab plus tislelizumab did not improve overall survival compared with pembrolizumab. The prespecified interim analysis was terminated for futility.
FDA Approval Expands Isatuximab Delivery Options in Multiple Myeloma
Clinical Summary: Design/Population: The phase 3 IRAKLIA trial randomized patients with relapsed or refractory multiple myeloma to receive subcutaneous isatuximab via an on-body injector or intravenous isatuximab, each combined with pomalidomide and dexamethasone.